The company had posted a net profit of Rs 74.14 crore for the corresponding period of the previous fiscal, Ajanta Pharma said in a filing to BSE.
Consolidated total income from the operations of the company also rose to Rs 425.73 crore for the quarter under review as against Rs 372.09 crore for the year-ago period.
"Despite challenges of foreign currency volatility and scarcity in the emerging markets, we have posted overall satisfactory growth during the quarter," Ajanta Pharma MD Yogesh Agrawal said.
Consolidated total income from operations of the company also rose to Rs 1,727.53 crore for the last fiscal. It was Rs 1,473.55 crore in 2014-15.
Shares of Ajanta Pharma were trading at Rs 1,492.70 per scrip in the afternoon trade on BSE, down 2.77 per cent from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
